Nuvation Bio (NUVB) to Announce Quarterly Earnings on Thursday

Nuvation Bio (NYSE:NUVB) is expected to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Nuvation Bio to announce earnings of ($0.1417) per share and revenue of $27.0270 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Nuvation Bio (NYSE:NUVB) last released its earnings results on Monday, May 4th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.04. Nuvation Bio had a negative return on equity of 44.10% and a negative net margin of 102.06%.The firm had revenue of $83.23 million for the quarter, compared to analysts’ expectations of $66.22 million. On average, analysts expect Nuvation Bio to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Nuvation Bio Stock Performance

NUVB stock opened at $6.17 on Tuesday. Nuvation Bio has a twelve month low of $2.18 and a twelve month high of $9.75. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of -14.34 and a beta of 1.52. The business’s fifty day simple moving average is $5.63 and its two-hundred day simple moving average is $5.23. The company has a quick ratio of 7.24, a current ratio of 7.44 and a debt-to-equity ratio of 0.15.

Insider Buying and Selling at Nuvation Bio

In related news, insider Kerry Wentworth sold 63,000 shares of Nuvation Bio stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $6.02, for a total transaction of $379,260.00. Following the transaction, the insider directly owned 53,000 shares of the company’s stock, valued at $319,060. This trade represents a 54.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Philippe Sauvage sold 47,668 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $6.01, for a total transaction of $286,484.68. Following the completion of the transaction, the chief financial officer directly owned 12,673 shares of the company’s stock, valued at $76,164.73. This trade represents a 79.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 235,668 shares of company stock valued at $1,419,495 in the last ninety days. Company insiders own 30.11% of the company’s stock.

Institutional Investors Weigh In On Nuvation Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Nuvation Bio by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 108,547 shares of the company’s stock worth $191,000 after purchasing an additional 4,608 shares in the last quarter. Millennium Management LLC boosted its position in shares of Nuvation Bio by 52.4% in the 1st quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock worth $6,642,000 after purchasing an additional 1,298,131 shares in the last quarter. Envestnet Asset Management Inc. acquired a new stake in shares of Nuvation Bio in the 2nd quarter worth $92,000. Creative Planning grew its stake in Nuvation Bio by 267.1% during the 2nd quarter. Creative Planning now owns 39,288 shares of the company’s stock worth $77,000 after buying an additional 28,585 shares during the last quarter. Finally, Cetera Investment Advisers purchased a new position in Nuvation Bio during the 2nd quarter worth $29,000. Hedge funds and other institutional investors own 61.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Royal Bank Of Canada reiterated an “outperform” rating on shares of Nuvation Bio in a report on Wednesday, July 22nd. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Nuvation Bio in a research report on Thursday, July 23rd. Citigroup reiterated a “market outperform” rating on shares of Nuvation Bio in a report on Wednesday, June 10th. Zacks Research raised Nuvation Bio from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nuvation Bio in a report on Friday, July 17th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.88.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.